JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

Search

Royalty Pharma PLC (Class A)

Open

SectorHealthcare

49.71 0.4

Overview

Share price change

24h

Current

Min

49.48

Max

50.45

Key metrics

By Trading Economics

Income

820M

356M

Sales

13M

622M

P/E

Sector Avg

27.893

67.147

Dividend yield

1.78

Profit margin

57.222

Employees

100

EBITDA

-74M

451M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.02% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.78%

2.36%

Next Earnings

6 maj 2026

Next Dividend date

10 cze 2026

Next Ex Dividend date

15 maj 2026

Market Stats

By TradingEconomics

Market Cap

3.7B

29B

Previous open

49.31

Previous close

49.71

News Sentiment

By Acuity

50%

50%

201 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Royalty Pharma PLC (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 cze 2025, 10:49 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

Peer Comparison

Price change

Royalty Pharma PLC (Class A) Forecast

Price Target

By TipRanks

11.02% upside

12 Months Forecast

Average 55 USD  11.02%

High 63 USD

Low 50 USD

Based on 7 Wall Street analysts offering 12 month price targets forRoyalty Pharma PLC (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

33 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

201 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat